Our mission at Prudentia Sciences

Accelerate investment in breakthrough therapies that change the world

Scientist in a white lab coat holding a tablet, smiling in front of laboratory glassware and reagent shelves

Pharmaceutical capsules and tablets used in drug development and evaluation

Prudentia Sciences Team

A team of experts, scientists, and technologists who have assessed assets, built companies, and seen how decisions actually get made.

Sadiqa Mahmood

CEO & Founder

Health Catalyst + Broad Institute of Harvard & MIT + Mass General Brigham

Sean O'Shea

CTO

Amwell + Fidelity + Betfair

John Reynders, PhD

Head of Strategy

Moderna + Alexion + J&J

Ben Klein

Head of Partnerships

Flatiron + Optum

Sharon Tan

Scientific Lead

Ultragenyx + enGene + Genzyme + Boston Scientific

Scientific Advisory Board

Scientific and clinical leaders ensuring every evaluation reflects how therapies are actually understood, developed, and advanced.

Mark Currie, PhD (SAB Chair)

Scientific Advisor, Coefficient Bio (Acquired by Anthropic) + Board Director and CSO, Ironwood Pharmaceuticals + Board Director, Science Exchange

Mary Lynne Hedley

Board Member, Eli Lilly and Veeva + Venture Partner, Third Rock Ventures + Co-founder and CSO of Tesaro (acquired by GSK)

David Nicholson, PhD

EVP and CRDO at Allergan + CTO and EVP, R&D at Bayer + Scientific Advisor, Formation Bio

Matt Leoni, MD

CMO, Merida Biosciences + SVP Global Clinical Development, Cerevel Therapeutics

Business Advisory Board

Operators and investors grounding Prudentia in how decisions get made: where science, capital, and deal dynamics meet.

Stuart Chaffee

Senior Advisor, General Atlantic + Co-Founder and Head of BD, Kymera Therapeutics (NASDAQ: KYMR) + CBO, Affnivax (Acquired by GSK) + CBO & CFO, Praxis Precision Medicines (IPO)

Travis May

CEO, Shaper Capital + Co-Founder and CEO, Datavant + Co-Founder and CEO, LiveRamp

Joe Von Rickenbach

Senior Advisor, General Atlantic + Co-Founder and CEO, Parexel + Co-Founder and CEO, Helio Vision, Inc.